Cypherpunk Technologies Inc. (CYPH)
NASDAQ: CYPH · Real-Time Price · USD
2.750
+0.990 (56.25%)
At close: Nov 14, 2025, 4:00 PM EST
2.700
-0.050 (-1.83%)
After-hours: Nov 14, 2025, 7:59 PM EST
Cypherpunk Technologies Employees
Cypherpunk Technologies had 52 employees as of December 31, 2024. The number of employees decreased by 2 or -3.70% compared to the previous year.
Employees
52
Change (1Y)
-2
Growth (1Y)
-3.70%
Revenue / Employee
n/a
Profits / Employee
-$981,654
Market Cap
155.79M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | -2 | -3.70% |
| Dec 31, 2023 | 54 | 10 | 22.73% |
| Dec 31, 2022 | 44 | 8 | 22.22% |
| Dec 31, 2021 | 36 | 6 | 20.00% |
| Dec 31, 2020 | 30 | 4 | 15.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Amazon.com | 1,578,000 |
| Berkshire Hathaway | 392,400 |
| Microsoft | 228,000 |
| Alphabet | 190,167 |
| Apple | 166,000 |
| Tesla | 125,665 |
| Taiwan Semiconductor Manufacturing Company | 83,825 |
| Meta Platforms | 78,450 |
CYPH News
- 2 days ago - Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results - PRNewsWire
- 2 days ago - Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy - PRNewsWire
- 25 days ago - Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 - PRNewsWire
- 5 weeks ago - Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PRNewsWire
- 5 weeks ago - Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PRNewsWire
- 7 weeks ago - Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 - PRNewsWire
- 3 months ago - Leap Therapeutics Reports Second Quarter 2025 Financial Results - PRNewsWire
- 5 months ago - Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives - PRNewsWire